Compare SBI & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SBI | RCEL |
|---|---|---|
| Founded | 1992 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 109.7M | 114.3M |
| IPO Year | N/A | N/A |
| Metric | SBI | RCEL |
|---|---|---|
| Price | $7.76 | $3.52 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $11.75 |
| AVG Volume (30 Days) | 39.5K | ★ 201.4K |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 4.52% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $72,401,000.00 |
| Revenue This Year | N/A | $13.12 |
| Revenue Next Year | N/A | $27.56 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 20.59 |
| 52 Week Low | $6.96 | $3.33 |
| 52 Week High | $8.00 | $14.16 |
| Indicator | SBI | RCEL |
|---|---|---|
| Relative Strength Index (RSI) | 44.40 | 37.63 |
| Support Level | $7.76 | $3.33 |
| Resistance Level | $7.84 | $3.58 |
| Average True Range (ATR) | 0.05 | 0.18 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 46.67 | 22.31 |
Western Asset Intermediate Muni Fd Inc is a diversified closed-end management investment company. The fund's objective is to provide a high level of current income exempt from Federal income taxes. Under normal market conditions, the Fund will invest at least 80% of its total assets in municipal obligations. In addition, under normal market conditions, the Fund will invest at least 80% of its total assets in debt securities that are, at the time of investment, rated investment grade by a nationally recognized statistical rating organization or, if unrated, of equivalent quality as determined by the investment manager. The Fund also maintains a dollar-weighted average effective maturity of between three and ten years.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently in rollout across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.